Correction to “Repurposing the Antidepressant Sertraline: A Systematic Scoping Review of Its Anticancer Mechanisms”
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCancer, Stress, Anesthesia, and Immune Response · Treatment of Major Depression · Cancer Research and Treatment
C. B. Blum, M.‐J. Dohrmann, L. McCarthy, M. McMenamin, and L. A. O'Callaghan, “Repurposing the Antidepressant Sertraline: A Systematic Scoping Review of Its Anticancer Mechanisms,” Pharmacology Research & Perspectives 13, no. 5 (2025): e70168, https://doi.org/10.1002/prp2.70168.
In the Discussion section, the reference Malard et al. [98] was cited instead of Li et al. [37].
“The effects of sertraline on DNA repair have been further elucidated by Malard et al. [98], who found that sertraline indirectly inhibits Rad51, a DNA repair protein, and modulates TCTP, a protein involved in p53 regulation and survival signaling.”
This should have read:
“The effects of sertraline on DNA repair have been further elucidated by Li et al. [37], who found that sertraline indirectly inhibits Rad51, a DNA repair protein, and modulates TCTP, a protein involved in p53 regulation and survival signaling.”
The correct reference is:
Li, Y., Sun, H., Zhang, C. et al. Identification of translationally controlled tumor protein in promotion of DNA homologous recombination repair in cancer cells by affinity proteomics. Oncogene 36, 6839–6849 (2017). https://doi.org/10.1038/onc.2017.289.
We apologize for this error.